Status:
UNKNOWN
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
Lead Sponsor:
Scripps Translational Science Institute
Collaborating Sponsors:
Scripps Health
Lexent Bio, Inc.
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
Detailed Description
The objective of this study is to determine the ability of cell free tumor DNA genomic profiling to predict disease relapse or progression while on therapy for advanced stage NSCLC in comparison to cu...
Eligibility Criteria
Inclusion
- Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC
- Baseline CT imaging available
Exclusion
- Patients unable to undergo biopsy for initial tissue diagnosis
- Patients who do not wish to pursue standard of care therapy
- Patients with another diagnosis of malignancy
Key Trial Info
Start Date :
March 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03878537
Start Date
March 14 2019
End Date
December 31 2021
Last Update
March 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Health/Scripps Clinic Hillcrest/Scripps Clinic Torrey Pines
San Diego, California, United States, 92103